about
The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.Viral sequence analysis of HIV-positive women and their infected children: insight on the timing of infection and on the transmission network.Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compoundsHigh prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral TreatmentEvolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of actionNovel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activitiesEffects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patientsHIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.HIV-1 coreceptor switch during 2 years of structured treatment interruptions.Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis.Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein.Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir.Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with <50copies/ml HIV-1 RNA.Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.Laboratory confirmation of clinically diagnosed malaria in a cohort of HIV-infected mothers and their children in Malawi.Serum Phosphate and Creatinine Levels in the First Year of Life in Infants Born to HIV-Positive Mothers Receiving Tenofovir-Based Combination Regimens During Pregnancy and Prolonged Breastfeeding in an Option B+ Program in Malawi.A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay.Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and RwandaThe role of IL-15 in challenging Acquired Immunodeficiency SyndromeResistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission preventionShort Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral TherapyThe Importance of Testing Genotypic Resistance in Proviral DNA of Patients Fully Responding to Highly Active Antiretroviral TherapyHIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/uL): an analysis of 338 clinical events from a randomized clinical trial*Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment1Quality of life outcomes of combination zidovudine–didanosine–nevirapine and zidovudine–didanosine for antiretroviral-naive advanced HIV-infected patientsHIV phenotype switching during antiretroviral therapy
P50
Q30863784-4FAE23A3-B39F-4404-BEB4-EA07905DDCF1Q34266269-1AED8AFB-86C4-4429-9886-09AD6BB1A032Q34394987-E26EB092-95D6-4678-84F3-2C732EC1C078Q34869426-B7327259-5EC7-47D7-AF0E-4077823B47F2Q34973832-4BABA221-EAD0-4364-B789-B483F1913089Q35091567-EDFD3D3C-28A4-419B-8589-12C5BAC34818Q35156558-0A10FE98-47E0-4C4D-953D-5F394C38EF85Q35861475-23287915-7BAB-4623-A467-A37F185F1B47Q35953203-81326A93-A09F-403F-8478-50F906A8A7EBQ37014638-99C46162-1D05-444C-83D2-5234B0E89656Q37107512-BE66BF4F-DBE4-42BC-9EEC-986A95A53A74Q37204137-9F50AB67-59D7-4D3A-9323-EE02FA220A1CQ38380240-BD9B2837-6BEE-4BDE-BD27-F718159FFDA0Q38385724-844D57C2-3B53-488A-8878-F91FA7676DE2Q38394525-DA09E78F-14F9-4AA7-9C4D-8BF15B716E91Q38894109-70BC9B93-D1BC-42C8-B61C-E7509A6D0694Q39249817-A7726B42-5BF9-4753-8E53-258CEA4F954EQ39520236-8CC14F35-C214-4DA5-A7E1-0C86204FEDDDQ40162203-3E2B4F24-B6A5-448A-BA82-6D3677465923Q40719420-8DFC0310-13A7-4175-98D0-A1A28C381A71Q40867191-485AB6AA-CCEA-4762-9B04-EDE92BAF1475Q40894200-DA3C07B7-2AFA-43A6-BD72-50C82F8BCE37Q42246779-6FC836AB-87DD-4589-B58E-E2506D36F2B5Q43822788-1928F7B5-3307-456E-90E3-BCF4D9B9D569Q45262691-C33AC577-07AF-4EEC-B859-BED6900B210BQ45391845-66CD17E8-FF4B-434F-99D1-B5F47719C272Q46142443-FC0522DA-2BA2-4FC1-BED5-C79544656785Q53749371-4E3BE893-CB02-42EF-BDB3-CB157E98F1D8Q53900357-E65008E5-7065-46F1-BDB4-38CBE37134E4Q54667196-85D989C6-641E-479F-86A0-71E2C641B8C3Q56918575-2FA3E246-8104-41B9-AF97-8B599709083CQ57573960-34DD50DB-07DE-45C8-A3E8-8C36EB05F03EQ57951608-592D3309-0D3C-4FFE-920B-21C4EDCC02DEQ58480348-0703165E-DD3C-4A0C-817D-3E84E2BEAA68Q58960841-A9E50097-D313-480C-B620-3C8ABA468AABQ58960862-81B95424-FFB8-4F5A-8B34-03F01E9C17BEQ58960867-FB39D79A-D6E7-48C1-8F71-65CAD231E840Q58960872-7F2B7B7B-80B9-4ED3-A2FC-32F73AD7F998Q58960879-C3AA33BD-3A17-46A5-8487-300F31595F51
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Clementina Maria Galluzzo
@ast
Clementina Maria Galluzzo
@en
Clementina Maria Galluzzo
@es
Clementina Maria Galluzzo
@nl
type
label
Clementina Maria Galluzzo
@ast
Clementina Maria Galluzzo
@en
Clementina Maria Galluzzo
@es
Clementina Maria Galluzzo
@nl
prefLabel
Clementina Maria Galluzzo
@ast
Clementina Maria Galluzzo
@en
Clementina Maria Galluzzo
@es
Clementina Maria Galluzzo
@nl
P1053
M-8912-2017
P106
P1153
6701508507
P21
P31
P3829
P496
0000-0003-1392-6569